Phase 1 Clinical Update of IMA203, an Autologous TCR T Targeting PRAME in Patients with PD1 Refractory Metastatic Melanoma
ASCO 2025
May 30 – June 3, 2025 Chicago, IL
Wermke, et al.
Read more